Eli Lilly and Company (NYSE:LLY) Shares Sold by Finer Wealth Management Inc.

Finer Wealth Management Inc. decreased its stake in Eli Lilly and Company (NYSE:LLY) by 2.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,511 shares of the company’s stock after selling 454 shares during the period. Eli Lilly and Company makes up 6.9% of Finer Wealth Management Inc.’s portfolio, making the stock its 3rd largest holding. Finer Wealth Management Inc.’s holdings in Eli Lilly and Company were worth $11,974,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Highline Wealth Partners LLC raised its holdings in shares of Eli Lilly and Company by 80.0% in the 4th quarter. Highline Wealth Partners LLC now owns 45 shares of the company’s stock worth $35,000 after buying an additional 20 shares in the last quarter. FPC Investment Advisory Inc. boosted its stake in shares of Eli Lilly and Company by 358.3% in the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock valued at $45,000 after purchasing an additional 43 shares in the last quarter. Prudent Man Investment Management Inc. bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth about $48,000. Compass Financial Services Inc acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $50,000. Finally, Fiduciary Advisors Inc. acquired a new position in Eli Lilly and Company in the fourth quarter valued at about $58,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $756.55 on Wednesday. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The firm has a market capitalization of $717.34 billion, a P/E ratio of 64.61, a PEG ratio of 1.40 and a beta of 0.51. The business has a 50-day moving average of $832.96 and a 200-day moving average of $821.54. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 0.13% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have recently issued reports on LLY. Citigroup cut their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Truist Financial lifted their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Guggenheim decreased their price objective on shares of Eli Lilly and Company from $973.00 to $928.00 and set a “buy” rating on the stock in a report on Monday. Wells Fargo & Company upped their target price on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Finally, Morgan Stanley lowered their price target on shares of Eli Lilly and Company from $1,146.00 to $1,124.00 and set an “overweight” rating for the company in a report on Wednesday, April 9th. Two equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,012.00.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.